NTRA Stock — Natera, Inc.

Up next

Next earnings call

Nov 5, 2026 Est · unconfirmed · in 5 wks

Latest filing: 10-Q

filed Aug 7, 2026

Q2 2026 earnings call transcript

call held Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

—

Year over year · more shares

Price change (1Y)

+156.8%

Trailing year

Short interest

3.3%

Latest settlement · 4.7 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026

Q2 FY26

TL;DR. Natera posted record Q2 2026 results with ~38% revenue growth and raised full-year revenue guidance by $100M at the midpoint to $2.85B–$2.91B, driven by record Signatera MRD volumes and multiple regulatory wins, while continuing to invest heavily in R&D including early cancer detection.

Bullish

+ Q2 revenue grew ~38% year-over-year to $752.8M with ex-true-up growth of ~40%.
+ Raised full-year 2026 revenue guidance by $100M at the midpoint to $2.85B–$2.91B.
+ Signatera clinical MRD units hit a record 283K, up ~56% YoY, with a record sequential increase of 34K units.
+ Gross margin expanded ~110 bps YoY to 64.5%, with continued ASP execution and positive cash generation.
+ Loss from operations narrowed to $75.8M from $110.4M YoY and net loss per share improved to ($0.47) from ($0.74).

Bearish

− Total operating expenses rose 21.5% YoY to $555.3M, driven by R&D growth including ~$100M in early cancer detection spend.
− Sequential gross margin ex-true-ups improved only ~50 bps despite blowout volumes, weighed down by new-product COGS.
− Q2 results still produced a net loss of $67.0M and accumulated deficit grew to $2.93B.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol High

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +67%

above

Price vs 50-day avg +27%

above

RSI (14) 82

overbought

MACD trend Positive

52-week position 100%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +29%

trailing

6-month return +104%

trailing

YTD return +80%

this year

Relative strength +91%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $325 › 200d $247 — 50d above 200d

Institutional flow Accumulating

+11% holders QoQ · +160 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

3.33% of float · ▼ -13.0% MoM · 4.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

853 holders — near 3-yr high, broad support

Squeeze score 65

elevated · 0–100

Fundamentals

Strong

Revenue growth −3%

Y/Y

EPS growth +1%

Y/Y

Free cash flow $109.1M

Balance sheet $359.2M

net cash

Quant / Vol

risk profile

High

Volatility 48%

annualized · 1-yr

Max drawdown −28%

past year

ATR 3.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 4 of last 4

Latest guidance · from the 8-K filed Aug 6, 2026

2026 total revenue · 2026 $2.85B – $2.91B

prior FY $2.31B midpoint +24.9% Y/Y

Gross margin · 2026 64% – 66%

Selling, general and administrative costs · 2026 $1.13B – $1.23B

Research and development costs · 2026 $800M – $900M

Gross margin % · 2026 GAAP 64% – 66%

Guided vs delivered · last 4 settled

Total revenue 2024

guided $1.49B – $1.52B

guided $1.49B – $1.52B $1.7B Beat +12.8%

Annual revenue 2023 annual

guided $1.04B – $1.05B

guided $1.04B – $1.05B $1.08B Beat +3.8%

Revenues full year

guided $615M – $625M

guided $615M – $625M $625.49M Beat +0.9%

Revenue 2020

guided $380M – $390M

guided $380M – $390M $391.01M Beat +1.6%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 2 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+67% Bullish

Price vs 50-day avg

+27% Bullish

RSI (14)

82 Bearish

MACD trend

Positive Bullish

52-week position

100% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $325 › 200d $247 — 50d above 200d

Institutional flow Accumulating

+11% holders QoQ · +160 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

3.33% of float · ▼ -13.0% MoM · 4.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

853 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $160 Now $413 · 100% Range high $415

vs 200-day avg +67% vs 50-day avg +27%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Tests reported in our laboratories	972,000	the three months ended June 30, 2026 filing	—
Total oncology units processed	296,700	the three months ended June 30, 2026 filing	—
Total reported units	985,500	the three months ended June 30, 2026 filing	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Diagnostics & Research — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
NTRA Natera, Inc. this stock	$59.47B	+80.4%	-2.8%	—	3.3%
TMO Thermo Fisher Scientific Inc.	$249.58B	+16.5%	+14.5%	36.3	1.4%
DHR Danaher Corp /De/	$155.42B	-3.2%	+8.5%	39.2	1.2%
A Agilent Technologies, Inc.	$48.90B	+26.6%	+6.4%	34.2	1.8%
IQV Iqvia Holdings Inc.	$45.12B	+19.3%	+41.6%	33.6	2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

853

% held: 96.8%
Net QoQ: +4.8M sh
Top holder: JPMORGAN CHASE & CO

Held Float

View

Held by Funds

Fund positions

737

View

Short & Settlement

Short Interest Falling

Shares short

4.8M

Days to cover: 4.7d
Change: -717.0K sh

View

Short Volume

Short vol %

50%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

2

Value: $656
As of: Sep 8, 2026

View

Off-Exchange

Off-exchange %

53.2%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Buy

Member

Josh Gottheimer

Amount: $1.0K–$15.0K
Traded: Sep 22, 2025

View

Financials

Revenue (FY)

$2.3B

Net income (FY): $-208.2M
EPS diluted: $-1.52

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 15, 2026
This year: 16

View

Proposed Sales

Value

$8.2M

Shares: 21.1K
Filed: Sep 23, 2026

View

Earnings & Events

Earnings Calls

Last call

Sep 15, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
NTRA	+5.8%	+28.9%	+103.6%	+28.4%	+80.4%
SPY	-0.7%	+0.1%	+12.2%	-0.6%	+11.8%
vs SPY	+6.4%	+28.7%	+91.4%	+29.0%	+68.6%

NTRA · Natera, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance